Stay updated on Immunotherapy with TILs in Metastatic Cancer Clinical Trial

Sign up to get notified when there's something new on the Immunotherapy with TILs in Metastatic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Immunotherapy with TILs in Metastatic Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 15 14 15 to 16 ... 15 16, indicating a potential update or modification in the medical and healthcare-related publications and documentation regarding the study on Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer.
    Difference
    0.3%
    Check dated 2024-05-17T02:27:01.000Z thumbnail image
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 06 ... 03 06 on the webpage has recently changed to 15 14 (Estimated) 15. This change likely represents an update or amendment to the ongoing study involving immunotherapy using tumor infiltrating lymphocytes for patients with metastatic cancer, specifically focusing on the rate of tumor regression in patients receiving autologous, minimally cultured TIL in conjunction with a preparative regimen, high-dose aldesleukin, and anti-PD-1.
    Difference
    0.3%
    Check dated 2024-05-16T01:26:41.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    12 days ago
    Change Detected
    Summary
    The value (Estimated) on the webpage has recently changed to . This change likely indicates an update or modification in the estimated completion date or status of the medical and healthcare-related study being monitored.
    Difference
    0.0%
    Check dated 2024-05-07T15:45:42.000Z thumbnail image
  7. Check
    13 days ago
    Change Detected
    Summary
    The value 04 17 04 16 04 17 has recently changed to 05 06 ... 05 03 (Estimated) 05 06. This change likely represents an update or new information related to the ongoing clinical trial involving immunotherapy using Tumor Infiltrating Lymphocytes for patients with metastatic cancer, specifically focusing on the use of autologous, minimally cultured TIL in conjunction with a non-myeloablative regimen, high-dose aldesleukin, and anti-PD-1.
    Difference
    0.5%
    Check dated 2024-05-06T14:45:08.000Z thumbnail image
  8. Check
    18 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:15:54.000Z thumbnail image

Stay in the know with updates to Immunotherapy with TILs in Metastatic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Immunotherapy with TILs in Metastatic Cancer Clinical Trial page.